Otros idiomas Benitec Biopharma Inc.

Acciones

BNTC

US08205P2092

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
9,49 ^USD	+0,21 %		+3,38 %	+193,81 %

13/05	Benitec Biopharma Inc. informa de los resultados del tercer trimestre y los nueve meses finalizados el 31 de marzo de 2024	CI
18/04	Benitec Biopharma Inc. informa de datos clínicos provisionales positivos del primer sujeto con OPMD tratado con BB-301 en el estudio de fase 1b/2a	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update	13/05
Benitec Biopharma : Releases Third Quarter 2024 Financial Results and Provides Operational Update - Form 8-K	13/05
Benitec Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	13/05
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference	01/05
Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors	22/04
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18/04
Top Midday Gainers	18/04
Top Premarket Gainers	18/04
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04
Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study	18/04
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million	18/04
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024	09/04
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update	13/02
Benitec Biopharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
Benitec Biopharma Doses First Participant in Trial of Treatment for Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy	30/11
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference	17/11
Earnings Flash (BNTC) BENITEC BIOPHARMA Posts Q1 Revenue $0M	13/11
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update	13/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Benitec Biopharma Inc.

Acciones

BNTC

US08205P2092

Otros idiomas

Filtros